Your browser doesn't support javascript.
loading
Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.
North, Thomas W; Villalobos, Andradi; Hurwitz, Selwyn J; Deere, Jesse D; Higgins, Joanne; Chatterjee, Payel; Tao, Sijia; Kauffman, Robert C; Luciw, Paul A; Kohler, James J; Schinazi, Raymond F.
Afiliación
  • North TW; Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia, USA Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA University of California Davis, Davis, California, USA.
  • Villalobos A; Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Hurwitz SJ; Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia, USA Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • Deere JD; University of California Davis, Davis, California, USA.
  • Higgins J; University of California Davis, Davis, California, USA.
  • Chatterjee P; Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia, USA Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • Tao S; Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia, USA Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • Kauffman RC; University of California Davis, Davis, California, USA.
  • Luciw PA; University of California Davis, Davis, California, USA.
  • Kohler JJ; Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia, USA Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • Schinazi RF; Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia, USA Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA rschina@emory.edu.
Antimicrob Agents Chemother ; 58(7): 3927-33, 2014 Jul.
Article en En | MEDLINE | ID: mdl-24777106
ABSTRACT
Using an established nonhuman primate model, rhesus macaques were infected intravenously with a chimeric simian immunodeficiency virus (SIV) consisting of SIVmac239 with the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase from clone HXBc2 (RT-SHIV). The impacts of two enhanced (four- and five-drug) highly active antiretroviral therapies (HAART) on early viral decay and rebound were determined. The four-drug combination consisted of an integrase inhibitor, L-870-812 (L-812), together with a three-drug regimen comprising emtricitabine [(-)-FTC], tenofovir (TFV), and efavirenz (EFV). The five-drug combination consisted of one analog for each of the four DNA precursors {using TFV, (-)-FTC, (-)-ß-D-(2R,4R)-1,3-dioxolane-2,6-diaminopurine (amdoxovir [DAPD]), and zidovudine (AZT)}, together with EFV. A cohort treated with a three-drug combination of (-)-FTC, TFV, and EFV served as treated controls. Daily administration of a three-, four-, or five-drug combination of antiretroviral agents was initiated at week 6 or 8 after inoculation and continued up to week 50, followed by a rebound period. Plasma samples were collected routinely, and drug levels were monitored using liquid chromatography-tandem mass spectrometry (LC-MS-MS). Viral loads were monitored with a standard TaqMan quantitative reverse transcriptase PCR (qRT-PCR) assay. Comprehensive analyses of replication dynamics were performed. RT-SHIV infection in rhesus macaques produced typical viral infection kinetics, with untreated controls establishing persistent viral loads of >10(4) copies of RNA/ml. RT-SHIV loads at the start of treatment (V0) were similar in all treated cohorts (P > 0.5). All antiretroviral drug levels were measureable in plasma. The four-drug and five-drug combination regimens (enhanced HAART) improved suppression of the viral load (within 1 week; P < 0.01) and had overall greater potency (P < 0.02) than the three-drug regimen (HAART). Moreover, rebound viremia occurred rapidly following cessation of any treatment. The enhanced HAART (four- or five-drug combination) showed significant improvement in viral suppression compared to the three-drug combination, but no combination was sufficient to eliminate viral reservoirs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Inmunodeficiencia Adquirida del Simio / Terapia Antirretroviral Altamente Activa Límite: Animals Idioma: En Revista: Antimicrob Agents Chemother Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Inmunodeficiencia Adquirida del Simio / Terapia Antirretroviral Altamente Activa Límite: Animals Idioma: En Revista: Antimicrob Agents Chemother Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos